Wells Fargo
ABVC icon

Wells Fargo’s ABVC BioPharma ABVC Stock Holding History

Wells Fargo’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-48
Closed -$63 – 6863
2024
Q1 		$63 Buy
48
+28
+140% +$36 ﹤0.01% 6768
2023
Q4 		$23 Buy
20
+2
+11% +$2 ﹤0.01% 7164
2023
Q3 		$19 Buy
18
+5
+38% +$12 ﹤0.01% 7212
2023
Q2 		$67 Buy
13
+1
+8% +$7 ﹤0.01% 6970
2023
Q1 		$78 Hold
12
– – ﹤0.01% 6990
2022
Q4 		$75 Hold
12
– – ﹤0.01% 6867
2022
Q3 		$0 Buy
+12
New +$101 ﹤0.01% 6581

Other funds holding ABVC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $3.64B AUM 14.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return

Wells Fargo's ABVC Position: Q2 2024 in Review

Wells Fargo sold out of ABVC BioPharma (ABVC) in Q2 2024, closing a stake of 48 shares — an estimated $63 sold.

Wells Fargo first reported a position in ABVC in Q3 2022 and held it in 7 quarters. The position peaked at $78 in Q1 2023. 11 funds tracked by Wall St. Rank hold ABVC as of Q2 2024.

  • Wells Fargo reported no remaining ABVC BioPharma position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 48 ABVC BioPharma shares in Q2 2024, an estimated $63.
  • Wells Fargo first reported a position in ABVC BioPharma in Q3 2022 and held it in 7 quarters.
  • Wells Fargo's ABVC BioPharma position peaked at $78 in Q1 2023.
  • 11 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.